Hsiao C-H, Yeh K-H, Chang Y-C, Tsai C-C
Division of Hematology-Oncology, Department of Internal Medicine, Far-Eastern Memorial Hospital, Taiwan; and Cancer Research Center, National Taiwan University, Taiwan.
Cancer Research Center; and Department of Oncology, College of Medicine, National Taiwan University, Taiwan.
West Indian Med J. 2013 Sep;62(7):651-3. doi: 10.7727/wimj.2012.317.
Although breast cancer is, unfortunately, not uncommon in women, a mere 0.04% of malignant breast tumours are primary angiosarcomas. Chemotherapy is advocated for treatment of breast angiosarcomas; however, no guidelines exist regarding optimal chemotherapeutics or protocols. Presently, the prognosis for breast angiosarcomas is poor. This case report describes a 24-year old woman diagnosed with primary breast angiosarcoma. She initially refused to receive treatment, but later returned to the hospital four years later with a haemopneumothorax. She was treated with rescue chemotherapy using a combination of high-dose tamoxifen plus ifosfamide and epirubicin (an anthracycline). She achieved a partial response, but died 16 months after therapy was initiated. More research is needed to devise novel chemotherapeutics and protocols to improve outcomes in women diagnosed with primary angiosarcomas of the breast.
不幸的是，乳腺癌在女性中并不罕见，但原发性血管肉瘤仅占恶性乳腺肿瘤的0.04%。化疗被推荐用于治疗乳腺血管肉瘤；然而，关于最佳化疗药物或方案尚无指南。目前，乳腺血管肉瘤的预后很差。本病例报告描述了一名24岁被诊断为原发性乳腺血管肉瘤的女性。她最初拒绝接受治疗，但四年后因血气胸返回医院。她接受了大剂量他莫昔芬联合异环磷酰胺和表柔比星（一种蒽环类药物）的挽救性化疗。她取得了部分缓解，但在开始治疗16个月后死亡。需要更多的研究来设计新的化疗药物和方案，以改善被诊断为原发性乳腺血管肉瘤女性的治疗结果。
